Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the 11 Best Short Squeeze Stocks to Buy Now.

The company’s stocks surge following the approval of the U.S. FDA Priority Review for sNDA for Revuforj (revumenib).

Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals

A scientist in a laboratory testing a monoclonal antibody for the treatment of cancer.

Headquartered in Massachusetts, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company engaged in developing novel combination therapies for cancer. The lead products include Revumenib, a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease. Currently, the company’s clinical pipeline also looks into applications in solid tumors and inflammatory conditions.

On June 24, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced receiving a U.S. FDA Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). This sNDA, reviewed under the FDA’s Real-Time Oncology Review (RTOR) program, allows for a more efficient review and close engagement between the sponsor and FDA. The Prescription Drug User Fee Act (PDUFA) target action date is October 25, 2025.

Following the announcements, many analysts have reiterated their Buy rating on the stock. The 1-year median price target for the stock, as per CNN’s 12 analysts, is $35, a 169.85% uptick from its current closing price as of August 12, 2025. Also, the company’s stocks are vulnerable to sudden price surges on positive news, with an elevated short float of 28.69% that tends to heighten the risk for short sellers.

While we acknowledge the risk and potential of SNDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.